A research team at the University of Massachusetts Amherst has demonstrated that a nanoparticle-based vaccine can effectively prevent melanoma, pancreatic cancer, and triple-negative breast cancer in mice. Remarkably, up to 88% of vaccinated mice remained tumor-free, depending on the cancer type. The vaccine also significantly reduced—or in some cases completely blocked—cancer spread in the body.
“By engineering these nanoparticles to activate the immune system via multi-pathway activation combined with cancer-specific antigens, we can prevent tumor growth with remarkable survival rates,” says Prabhani Atukorale, assistant professor of biomedical engineering at UMass Amherst.
Atukorale’s earlier studies showed that the same nanoparticle design could shrink or eliminate existing tumors. The new findings now reveal its powerful potential as a preventive strategy as well.
Testing Melanoma-Specific Antigens
In the first phase, researchers paired the nanoparticle platform with well-established melanoma peptides. This formulation activated T cells and primed them to recognize and destroy melanoma cells. Three weeks after vaccination, the mice were challenged with melanoma.
As reported by scitechdaily, the results were dramatic: 80% of mice receiving the nanoparticle “super-adjuvant” vaccine remained tumor-free for the full 250-day study period. In contrast, all mice receiving a traditional vaccine or no vaccine developed tumors and died within 35 days.
Furthermore, the nanoparticle vaccine prevented melanoma from spreading to the lungs. When researchers introduced melanoma cells systemically, none of the vaccinated mice developed lung tumors, while all unvaccinated mice did.
Establishing Long-Lasting Immune Memory
Atukorale describes this protection as “memory immunity,” referring to the immune system’s long-term and body-wide surveillance. “Memory is not only sustained locally. We have memory systemically, which is very important. The immune system spans the entire geography of the body,” she says.
Using Tumor Lysate for Broader Protection
Customized antigens for every cancer type typically require advanced genomic tools. To overcome this challenge, the team conducted a second experiment using tumor lysate—killed cancer cells taken directly from the tumor.
After vaccination, mice were exposed to melanoma, pancreatic ductal adenocarcinoma, or triple-negative breast cancer cells. The results were compelling:
• 88% of pancreatic cancer cases showed tumor rejection
• 75% of breast cancer cases showed tumor rejection
• 69% of melanoma cases showed tumor rejection
Moreover, every vaccinated mouse that remained tumor-free resisted metastasis during later systemic exposure to cancer cells.
“The tumor-specific T-cell responses we generate are the key to survival benefits,” explains Griffin Kane, postdoctoral researcher and first author. “Innate immune cells show intense activation with this formulation, prompting them to present antigens and prime tumor-killing T cells.”
How the Nanoparticle Vaccine Works
Vaccines rely on two essential components: the antigen, which teaches the immune system what to target, and the adjuvant, which stimulates a strong immune response. Many promising cancer immunotherapy adjuvants fail to combine well, similar to oil and water.
To solve this, the Atukorale Lab created a lipid nanoparticle “super-adjuvant” capable of encapsulating and delivering two immune-stimulating ingredients simultaneously. This design mimics natural pathogen signals and ensures multi-pathway immune activation.
Toward a Versatile Cancer Vaccine Platform
The research team envisions this nanoparticle system as a flexible platform for multiple cancer types. It holds promise for both treatment and prevention, particularly for individuals at high risk of cancer.
This technology also laid the foundation for NanoVax Therapeutics, a startup founded by Atukorale and Kane to advance clinical translation. “This platform is the core technology behind our company,” says Kane. “Our goal is to move these innovations closer to improving patients’ lives.”